Radiation therapy

Brain Tumor Diagnosis & Treatment Market Research Report by Treatment, by Diagnosis, by Type - Global Forecast to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Thursday, October 8, 2020
Medicine, Clinical medicine, Radiobiology, Branches of biology, RTT, Brain tumor, Radiation therapy, Radiosurgery, Fibrillary astrocytoma, Oligoastrocytoma

Brain Tumor Diagnosis & Treatment Market Research Report by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Radiosurgery, and Surgery), by Diagnosis (CT Scan, EEG, Molecular Testing, MRI, and PET-CT Scan), by Type - Global Forecast to 2025 - Cumulative Impact of COVID-19

Key Points: 
  • Brain Tumor Diagnosis & Treatment Market Research Report by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Radiosurgery, and Surgery), by Diagnosis (CT Scan, EEG, Molecular Testing, MRI, and PET-CT Scan), by Type - Global Forecast to 2025 - Cumulative Impact of COVID-19
    This research report categorizes the Brain Tumor Diagnosis & Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Treatment, the Brain Tumor Diagnosis & Treatment Market studied across Chemotherapy, Immunotherapy, Radiation Therapy, Radiosurgery, Surgery, and Targeted Drug Therapy.
  • Based on Diagnosis, the Brain Tumor Diagnosis & Treatment Market studied across CT Scan, EEG, Molecular Testing, MRI, and PET-CT Scan.
  • Based on Type, the Brain Tumor Diagnosis & Treatment Market studied across Primary Brain Tumor and Secondary Brain Tumor.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Tumor Diagnosis & Treatment Market during the forecast period?

Burlington Medical and Radiological Care Services Partner to Protect Patients and Staff from Health Care-Associated Infections

Retrieved on: 
Wednesday, October 7, 2020
Articles, Health, Medical device, COVID-19 pandemic, Medicine, Infection, Occupational safety and health, Radiation therapy

Additionally, the COVID-19 pandemic has heightened awareness in health care facilities related to infection control.

Key Points: 
  • Additionally, the COVID-19 pandemic has heightened awareness in health care facilities related to infection control.
  • Many health systems are placing attention on the sharing of x-ray aprons between employees and medical device sales representatives as a potential for pathogen transmission.
  • Burlington Medical is an expert in the health and safety concerns of providers working in a radiation environment.
  • To learn more about Burlington Medical, their wholistic radiation protection, or their new core material, visit https://www.burmed.com .

Simplify Disc 1 and 2-Level Abstracts to be Presented in the Best Papers Section at the North American Spine Society Meeting (NASS) Annual Meeting

Medical physics, Physical sciences, Radioactivity, Radiobiology, Radiation, Nuclear physics, Radiation therapy, Medical imaging, Ionizing radiation, Magnetic resonance imaging

It is composed of advanced, primarily non-metal materials (PEEK-on-ceramic) to permit the full diagnostic imaging capability of MRI, potentially minimizing patient exposure to ionizing radiation.

Key Points: 
  • It is composed of advanced, primarily non-metal materials (PEEK-on-ceramic) to permit the full diagnostic imaging capability of MRI, potentially minimizing patient exposure to ionizing radiation.
  • The three-piece disc, with a semi-constrained mobile core, is designed to mimic/replicate the natural biomechanical motion of a healthy disc.
  • Implantation of the Simplify Disc is accomplished in a straightforward, three-step procedure.
  • The Simplify Disc is CE Marked in Europe and commercially available in select European markets.

GenesisCare Acquires Ten New ExacTrac Dynamic Systems for Advanced Cancer Treatment Following FDA Clearance

Retrieved on: 
Wednesday, October 7, 2020
Oncology, Medical devices, Health, FDA, Surgery, Radiology, Medicine, Clinical medicine, Medical specialties, Neurosurgery, Radiobiology, Radiosurgery, Stereotactic surgery, Radiation therapy, Therapy, Oncology, Draft:Surface Guided Radiation Therapy, Mount Miriam Cancer Hospital, Brainlab, 21st Century Oncology, GenesisCare

This follows GenesisCare s acquisition of major integrated cancer care provider, 21st Century Oncology , increasing access to advanced cancer care for patients across US communities.

Key Points: 
  • This follows GenesisCare s acquisition of major integrated cancer care provider, 21st Century Oncology , increasing access to advanced cancer care for patients across US communities.
  • ExacTrac Dynamic will allow GenesisCare physicians to deliver stereotactic radiosurgery, a non-invasive form of radiation therapy which delivers precisely targeted radiation in fewer high-dose treatments than traditional therapies.
  • ExacTrac Dynamic systems have already been rolled out in Australia and the UK, providing patients access to the latest advancements in radiation therapy, including stereotactic radiosurgery and tattoo-free treatment.
  • Building upon the first generation ExacTrac X-Ray, the new ExacTrac Dynamic system expands clinical workflows beyond traditional stereotactic capabilities with new surface-guided and thermal technology.

Advanced Radiation Therapy Announces the Launch of ConfidenceRT™

Retrieved on: 
Tuesday, October 6, 2020
Health, Medicine, Medical physics, Radiation therapy, Radioactivity, Radiobiology, Radiation oncologist, Breast cancer, Oncology, Therapy, Adjuvant therapy

TYNGSBORO, Mass., Oct. 6, 2020 /PRNewswire-PRWeb/ -- ConfidenceRT has been launched in the U.S. MedTech marketplace and is available to radiation therapy clinics and hospitals immediately.

Key Points: 
  • TYNGSBORO, Mass., Oct. 6, 2020 /PRNewswire-PRWeb/ -- ConfidenceRT has been launched in the U.S. MedTech marketplace and is available to radiation therapy clinics and hospitals immediately.
  • "We have been developing this technology for some time now and have designed it to meet the clinical challenges of treating breast cancer with radiation in ways which optimize the cosmetic and clinical outcomes in consideration of the adjuvant surgical techniques commonly employed today," says Piran Sioshansi, President and CEO of Advanced Radiation Therapy (ART).
  • By leveraging the imaging quality of breast diagnostic technology, ConfidenceRT provides radiation oncologists with high-resolution images in real-time allowing them to both easily identify the tumor bed and treat patients quickly on a single platform.
  • Bill Dowd, Chief Commercialization Officer at ART, commented that "ConfidenceRT is the right product for this market at the right time.

Sirtex Medical appoints Francis Jannot as Executive Vice President of International Sales

Retrieved on: 
Tuesday, October 6, 2020
Anatomy, Radiation therapy, Sirtex, Aortic valve, Heart valve, Percutaneous aortic valve replacement, Boston Scientific

WOBURN, Mass., Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.

Key Points: 
  • WOBURN, Mass., Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.
  • Under Mr. Jannot's leadership, the implementation of best-in-class sales processes and both organic and inorganic growth in international marketing will be leading areas of focus.
  • Prior to joining Sirtex, Mr. Jannot worked for Boston Scientific, where he served as Vice President of Global Commercial Operations for the structural heart valves business unit.
  • Prior to working for Boston Scientific, Francis was Vice President of Sales and Marketing Europe at Symetis, a start-up dedicated to the transcatheter aortic valve implantation market.

Sirtex Medical appoints Francis Jannot as Executive Vice President of International Sales

Retrieved on: 
Tuesday, October 6, 2020
Anatomy, Radiation therapy, Sirtex, Aortic valve, Heart valve, Percutaneous aortic valve replacement, Boston Scientific

WOBURN, Massachusetts, Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.

Key Points: 
  • WOBURN, Massachusetts, Oct. 6, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.
  • Under Mr. Jannot's leadership, the implementation of best-in-class sales processes and both organic and inorganic growth in international marketing will be leading areas of focus.
  • Prior to joining Sirtex, Mr. Jannot worked for Boston Scientific, where he served as Vice President of Global Commercial Operations for the structural heart valves business unit.
  • Prior to working for Boston Scientific, Francis was Vice President of Sales and Marketing Europe at Symetis, a start-up dedicated to the transcatheter aortic valve implantation market.

Radiodermatitis Market to Hit $609.68 Mn, Globally, by 2027 at 4.1% CAGR, Says Allied Market Research

Retrieved on: 
Monday, October 5, 2020
Burns, Radiation burn, Radiation therapy, Sun tanning, Occupational safety and health, Coronavirus disease, Impact of the COVID-19 pandemic, Health, Clinical medicine, Medicine

As per the report, the global radiodermatitis industry was pegged at $477.48 million in 2019, and is anticipated to reach $609.68 million by 2027, growing at a CAGR of 4.1% from 2020 to 2027.

Key Points: 
  • As per the report, the global radiodermatitis industry was pegged at $477.48 million in 2019, and is anticipated to reach $609.68 million by 2027, growing at a CAGR of 4.1% from 2020 to 2027.
  • Request for Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/4498?reqf...
    Rise in the geriatric population, surge in prevalence of cancer, and increase in adoption of radiotherapy have boosted the growth of the global radiodermatitis market.
  • However, the demand for radiodermatitis is expected to decline during the pandemic, due to various manufacturers in radiodermatitis have been facing issues in the supply of their products.
  • By product, the topical segment held the lion's share in 2019, accounting for more than four-fifths of the global radiodermatitis market, owing to easier application, cost-effectiveness, and its bioavailability.

Radiodermatitis Market to Hit $609.68 Mn, Globally, by 2027 at 4.1% CAGR, Says Allied Market Research

Retrieved on: 
Monday, October 5, 2020
Burns, Radiation burn, Radiation therapy, Sun tanning, Compound annual growth rate, Academic disciplines, Articles

As per the report, the global radiodermatitis industry was pegged at $477.48 million in 2019, and is anticipated to reach $609.68 million by 2027, growing at a CAGR of 4.1% from 2020 to 2027.

Key Points: 
  • As per the report, the global radiodermatitis industry was pegged at $477.48 million in 2019, and is anticipated to reach $609.68 million by 2027, growing at a CAGR of 4.1% from 2020 to 2027.
  • Request for Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/4498?reqf...
    Rise in the geriatric population, surge in prevalence of cancer, and increase in adoption of radiotherapy have boosted the growth of the global radiodermatitis market.
  • However, higher radiodermatitis cost hampers the market growth.
  • By product, the topical segment held the lion's share in 2019, accounting for more than four-fifths of the global radiodermatitis market, owing to easier application, cost-effectiveness, and its bioavailability.

BioCurity Pharmaceuticals Inc. ('BioCurity') Announces Issuance of European Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy

Retrieved on: 
Friday, October 2, 2020
Health, Medicine, Clinical medicine, Medical physics, Oncology, Cancer treatments, RTT, Radiation therapy, Radioactivity, Therapy, Chemotherapy, Cancer

This European patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen.

Key Points: 
  • This European patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen.
  • Having international patents positions BioCurity as a global leader in drug development using cerium oxide nanoparticles to mitigate radiation side effects," said Dr. Cheryl Baker, PhD.
  • Short and long-term side effects from radiation therapy can impair a cancer patient's medical treatment plan and can leave cancer survivors with permanent adverse conditions.
  • "There is an estimated 3-billion-dollar healthcare cost for in-patient treatment of medical side effects from radiation therapy in the United States annually.